Nothing Special   »   [go: up one dir, main page]

AR065628A1 - Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo - Google Patents

Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo

Info

Publication number
AR065628A1
AR065628A1 ARP080100936A ARP080100936A AR065628A1 AR 065628 A1 AR065628 A1 AR 065628A1 AR P080100936 A ARP080100936 A AR P080100936A AR P080100936 A ARP080100936 A AR P080100936A AR 065628 A1 AR065628 A1 AR 065628A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
independently
alkyl
hydrogen
haloalkyl
Prior art date
Application number
ARP080100936A
Other languages
English (en)
Inventor
Jianmin Fu
Jean-Jacques Cadieux
Shifeng Liu
Nagasree Chakka
Mikhail Chafeev
Rajender Kamboj
Vishnumurthy Kodumuru
Johnathan Langille
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of AR065628A1 publication Critical patent/AR065628A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/08—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing three- or four-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente también incluye composiciones farmacéuticas que comprenden los compuestos. Los compuestos son utiles en el tratamiento de trastornos por carencia de hierro en el organismo. Reivindicacion 1: Un compuesto caracterizado porque responde ala formula (1): donde: n y m son cada uno en forma independiente 0, 1 o 2; R1 y R2 son cada uno en forma independiente un enlace directo, -C(R9)2-, -S-, -O-, -C(O)-, -N(R9)- o -CH2R10-CH2-; R3 y R4 son diferentes y cada uno se selecciona en formaindependiente entre -R11-S-C(=NR12)N(R12)R13, -R11-O-C(=NR12)N(R12)R13, -R11-C(=NR12)N(R12)R13, o -R11-N(R9)-C(=NR12)N(R12)R13; o R3 y R4 son iguales y se seleccionan entre -R11-S-C(=NR12)N(R12)R13, -R11-O-C(=NR12)N(R12)R13, -R11-C(=NR12)N(R12)R13,o -R11-N(R9)-C(=NR12)N(R12)R13; R5 y R6 son diferentes y cada uno se selecciona en forma independiente entre hidrogeno, alquilo, halo, haloalquilo, -R11-CN, -R11-NO2, -R11-N(R14)2, -R11-C(O)OR14, -R-C(O)N(R14)2, -R11-S-C(=NR12)N(R12)R13, -R11-O-C(=NR12)N(R12)R13, -R11-C(=NR12)N(R12)R13, -R11-N(R9)-C(=NR12)N(R12)R13, -N(R14)S(O)tR15, -S(O)tOR15, -S(O)pR14, o S(O)tN(R14)2, donde cada t es en forma independiente 1 o 2 y cada p es 0, 1 o 2; o R5 y R6 son iguales y se seleccionan entrehidrogeno, alquilo, halo, haloalquilo, -R11-CN, -R11-NO2, -R11-N(R14)j2, -R11-C(O)OR14, -R11-C(O)N(R14)2, -R11-S-C(=NR12)N(R12)R13, -R11-O-C(=NR12)N(R12)R13, -R11-C(=NR12)N(R12)R13, -R11-N(R9)-C(=NR12)N(R12)R13, -N(R14)S(O)tR15, -S(O)tOR15, -S(O)pR14, o -S(O)tN(R14)2, donde cada t es en forma independiente 1 o 2 y cada p es 0, 1 o 2; cada R7 y R8 se selecciona en forma independiente entre el grupo que consiste de alquilo, alquenilo, alquinilo, halo, haloalquilo, haloalquenilo,haloalcoxi, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, aralquenilo opcionalmente sustituido, heterociclilo opcionalmente sustituido,heterociclilalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilalquilo opcionalmente sustituido, -R11-CN, -R11-NO2, -R11-OR9, -R5-OS(O)2R15, -R11-N(R14)2, -R11-S(O)pR14, -R11-C(O)R14, -R11-C(S)R15, -R11-C(O)OR4, -R11-OC(O)R14, -R11-C(S)OR14, -R11-C(O)N(R14)2, -R11-C(S)N(R14)2, - N=C(R15)2, -R11-N(R14)C(O)R15, -R11-N(R14)C(S)R15, -R11-N(R14)C(O)OR14, -R11-N(R14)C(S)OR14, -R11-N(R14)C(O)N(R14)2, -R11- N(R14)C(S)N(R14)2, -R11-N(R14)S(O)tR14, -R11-N(R14)S(O)tN(R14)2, -R11-S(O)tN(R14)2, -R11-N(R14)C(=NR14)N(R14)2, y -R11-N(R14)C(N=C(R14)2)N(R14)2, donde cada p es en forma independiente 0, 1, o 2 y cada t es en forma independiente 1 o 2; cada R9 es hidrogeno, alquilo, alquenilo, alquinilo,haloalquilo, alcoxialquilo, cicloalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, heterociclilalquiloopcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroarilalquilo opcionalmente sustituido; R10 es -C(R9)2-, -S-, -O- o -N(R9)-; cada R11 es en forma independiente un enlace directo o una cadena alquileno lineal o ramificada; cadaR12 y R13 es en forma independiente hidrogeno, alquilo, o -OR9; cada R14 es en forma independiente hidrogeno, alquilo, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroariloopcionalmente sustituido; y cada R15 es alquilo; como un estereoisomero, enantiomero, tautomero del mismo o mezclas de los mismos; o una sal, solvato o prodroga aceptable para uso farmacéutico del mismo.
ARP080100936A 2007-03-07 2008-03-06 Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo AR065628A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89358507P 2007-03-07 2007-03-07

Publications (1)

Publication Number Publication Date
AR065628A1 true AR065628A1 (es) 2009-06-17

Family

ID=39512833

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100936A AR065628A1 (es) 2007-03-07 2008-03-06 Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo

Country Status (13)

Country Link
US (1) US20090069408A1 (es)
EP (1) EP2061755A1 (es)
JP (1) JP2010520884A (es)
CN (1) CN101616892A (es)
AR (1) AR065628A1 (es)
AU (1) AU2008222666A1 (es)
BR (1) BRPI0808043A2 (es)
CA (1) CA2678895A1 (es)
CL (1) CL2008000666A1 (es)
MX (1) MX2009009466A (es)
RU (1) RU2009136996A (es)
TW (1) TW200845961A (es)
WO (1) WO2008109840A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2068855A2 (en) * 2007-06-05 2009-06-17 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
JP2013502399A (ja) 2009-08-20 2013-01-24 ヴィフォール （インターナショナル） アクチェンゲゼルシャフト 新規なキノリン系ヘプシジン拮抗薬
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
EP2475643A1 (de) 2009-09-07 2012-07-18 Vifor (International) Ag Neue ethandiamin-hepcidin-antagonisten
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
MA44474A (fr) 2015-10-23 2019-01-30 Vifor Int Ag Nouveaux inhibiteurs de la ferroportine
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
CN114163417B (zh) * 2021-12-06 2023-08-04 郑州海阔光电材料有限公司 一种3-溴硫芴的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
EP0661284A1 (en) * 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
US6310243B1 (en) * 1994-09-23 2001-10-30 Nycomed Imaging As Iodinated x-ray contrast media
US6080587A (en) * 1998-01-23 2000-06-27 Eli Lilly And Company Method for preparing and selecting pharmaceutically useful sulfur-bridged bi- and triaromatic ring compounds from a structurally diverse universal library
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US20060269498A1 (en) * 2005-05-17 2006-11-30 Gerard Malle Hair shaping composition comprising at least one polyguanidine other than hydroxide
EP2068855A2 (en) * 2007-06-05 2009-06-17 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders

Also Published As

Publication number Publication date
JP2010520884A (ja) 2010-06-17
MX2009009466A (es) 2009-09-15
TW200845961A (en) 2008-12-01
CA2678895A1 (en) 2008-09-12
RU2009136996A (ru) 2011-04-20
AU2008222666A1 (en) 2008-09-12
BRPI0808043A2 (pt) 2014-06-24
WO2008109840A1 (en) 2008-09-12
CN101616892A (zh) 2009-12-30
CL2008000666A1 (es) 2008-06-13
EP2061755A1 (en) 2009-05-27
US20090069408A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
AR065628A1 (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
AR053710A1 (es) Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
ES2381683T3 (es) Compuestos de espiro-oxindol y sus usos como agentes terapéuticos
AR056317A1 (es) Compuestos de oxindol y composicion farmaceutica
AR073898A1 (es) Compuestos de espiro-oxindol y su uso como agentes terapeuticos.
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CR10250A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
PE20120911A1 (es) Derivados de prolina como inhibidores de catepsina
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
AR055774A1 (es) Fenilacetamidas apropiadas como inhibidores de proteina quinasa
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR063278A1 (es) Compuestos de espiro-oxindol, una composicion farmaceutica que los comprende y su uso para el tratamiento de enfermedades o condiciones mediadas por los canales de sodio.
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR043014A1 (es) Amino-1,3,5-triazinas n-sustituidas con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas, y su uso como herbicidas y reguladores del crecimiento de las plantas
AR049647A1 (es) Cis-imidazolinas
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
AR087196A1 (es) Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii
AR059176A1 (es) Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis.
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR064349A1 (es) Derivados de dihidropiridina de utilidad como inhibidires de la proteina quinasa, un proceso para su preparacion, aldehidos intermediarios de su sintesis, una composicion farmaceutica que los comprende y su utilizacion en la produccion de medicamentos para el tratamiento de trastornos proliferativos
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
AR065194A1 (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio
AR083069A1 (es) Analogos de nucleotidos sustituidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal